Abstract
Objective evaluation of tumor response to therapy has been a basis for advances of effective cancer therapies, and has contributed significantly to marked progress in the treatment approaches for cancer patients in the past decades. Imaging plays a key role in objectively characterizing tumor response and progression during therapy, thus providing trial endpoints that help to determine regulatory approvals of new agents and informing treating physicians for their treatment decisions. Several conventional tumor response criteria based on imaging have been proposed and utilized in the past few decades, and have been updated to meet the needs for the current era of cancer treatment. This chapter will (1) review the concept and goals of tumor response criteria, (2) describe introduction and revisions of Response Evaluation Criteria for Solid Tumors (RECIST) as a major standardized criteria to date, and (3) discuss the limitations of RECIST. This chapter focuses on the tumor response criteria for solid tumors, and criteria for lymphoma and other hematologic malignancies are discussed separately in the subsequent chapter in the book (chapter “Therapy Response Imaging in Lymphoma and Hematologic Malignancies”).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
Erasmus JJ, Gladish GW, Broemeling L et al (2003) Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 21:2574–2582
Gavrielides MA, Kinnard LM, Myers KJ, Petrick N (2009) Noncalcified lung nodules: volumetric assessment with thoracic CT. Radiology 251:26–37
Krajewski KM, Nishino M, Ramaiya NH, Choueiri TK (2015) RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. AJR Am J Roentgenol 204:W282–W288
Kuhl CK, Alparslan Y, Schmoee J et al (2019) Validity of RECIST version 1.1 for response assessment in metastatic cancer: a prospective, multireader study. Radiology 290(2):349–356
Longo DL (2012) Tumor heterogeneity and personalized medicine. N Engl J Med 366:956–957
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214
Mozley PD, Schwartz LH, Bendtsen C, Zhao B, Petrick N, Buckler AJ (2010) Change in lung tumor volume as a biomarker of treatment response: a critical review of the evidence. Ann Oncol 21:1751–1755
Mozley PD, Bendtsen C, Zhao B et al (2012) Measurement of tumor volumes improves RECIST-based response assessments in advanced lung cancer. Transl Oncol 5:19–25
Nishino M (2018) Tumor response assessment for precision cancer therapy: response evaluation criteria in solid tumors and beyond. Am Soc Clin Oncol Educ Book 38:1019–1029
Nishino M, Jagannathan JP, Ramaiya NH, Van den Abbeele AD (2010a) Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know. AJR Am J Roentgenol 195:281–289
Nishino M, Jackman DM, Hatabu H et al (2010b) New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol 195:W221–W228
Nishino M, Guo M, Jackman DM et al (2011) CT tumor volume measurement in advanced non-small-cell lung cancer: performance characteristics of an emerging clinical tool. Acad Radiol 18:54–62
Nishino M, Jagannathan JP, Krajewski KM et al (2012) Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am J Roentgenol 198:737–745
Nishino M, Cardarella S, Jackman DM et al (2013a) RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0. AJR Am J Roentgenol 201:W64–W71
Nishino M, Dahlberg SE, Cardarella S et al (2013b) Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI. J Thorac Oncol 8:1059–1068
Nishino M, Hatabu H, Johnson BE, McLoud TC (2014a) State of the art: response assessment in lung cancer in the era of genomic medicine. Radiology 271:6–27
Nishino M, Jackman DM, DiPiro PJ, Hatabu H, Janne PA, Johnson BE (2014b) Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: an exercise to maximize the utility of each measure to assess response to therapy. Clin Radiol 69:841–848
Nishino M, Dahlberg SE, Fulton LE et al (2016) Volumetric tumor response and progression in EGFR-mutant NSCLC patients treated with erlotinib or gefitinib. Acad Radiol 23:329–336
Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216
Zhao B, Oxnard GR, Moskowitz CS et al (2010) A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. Clin Cancer Res 16:4647–4653
Zhao B, Lee SM, Lee HJ et al (2014) Variability in assessing treatment response: metastatic colorectal cancer as a paradigm. Clin Cancer Res 20:3560–3568
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Nishino, M. (2020). Conventional Tumor Response Criteria and Limitations. In: Nishino, M. (eds) Therapy Response Imaging in Oncology. Medical Radiology(). Springer, Cham. https://doi.org/10.1007/978-3-030-31171-1_1
Download citation
DOI: https://doi.org/10.1007/978-3-030-31171-1_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-31170-4
Online ISBN: 978-3-030-31171-1
eBook Packages: MedicineMedicine (R0)